SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Clinical trials for SMALL LYMPHOCYTIC LYMPHOMA (SLL) explained in plain language.
Never miss a new study
Get alerted when new SMALL LYMPHOCYTIC LYMPHOMA (SLL) trials appear
Sign up with your email to follow new studies for SMALL LYMPHOCYTIC LYMPHOMA (SLL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New antibody drug shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis trial tests an antibody called epcoritamab in 666 people with B-cell lymphoma that has come back or not responded to treatment. The drug is designed to help the immune system attack cancer cells. The study looks at safety, the right dose, and how well the drug works.
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
CLL breakthrough: stopping treatment may be possible for some patients
Disease control OngoingThis study looks at whether people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have undetectable cancer cells after venetoclax treatment can stop taking the drug and stay in remission for at least a year. Researchers will monitor 81 participant…
Matched conditions: SMALL LYMPHOCYTIC LYMPHOMA (SLL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC